F Beeldens

879 total citations
11 papers, 642 citations indexed

About

F Beeldens is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, F Beeldens has authored 11 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 4 papers in Public Health, Environmental and Occupational Health and 3 papers in Molecular Biology. Recurrent topics in F Beeldens's work include Acute Myeloid Leukemia Research (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Hematopoietic Stem Cell Transplantation (3 papers). F Beeldens is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Hematopoietic Stem Cell Transplantation (3 papers). F Beeldens collaborates with scholars based in Belgium, Italy and Netherlands. F Beeldens's co-authors include Petra Muus, Stefan Suciu, Dominik Selleslag, Liliana Baila, Boris Labar, Helmut R. Salih, Aristoteles Giagounidis, Michael Lübbert, Théo de Witte and Uwe Platzbecker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

F Beeldens

11 papers receiving 633 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F Beeldens Belgium	6	526	297	150	133	84	11	642
Jan Davis United States	6	619 1.2×	436 1.5×	229 1.5×	194 1.5×	89 1.1×	7	819
Rainer Krahl Germany	14	754 1.4×	250 0.8×	195 1.3×	350 2.6×	106 1.3×	42	868
Jiří Mayer Czechia	5	744 1.4×	460 1.5×	224 1.5×	179 1.3×	152 1.8×	15	885
Chun Yew Fong Australia	12	425 0.8×	266 0.9×	93 0.6×	114 0.9×	92 1.1×	50	600
Maria Cristina Sauerland Germany	16	684 1.3×	331 1.1×	322 2.1×	164 1.2×	122 1.5×	36	880
Leandro de Pádua Silva United States	9	572 1.1×	226 0.8×	195 1.3×	84 0.6×	84 1.0×	25	746
Birgitte Preiss Denmark	12	461 0.9×	207 0.7×	142 0.9×	156 1.2×	143 1.7×	25	554
Ali Tabarroki United States	10	448 0.9×	348 1.2×	44 0.3×	225 1.7×	60 0.7×	27	679
Mary‐Frances McMullin United Kingdom	9	602 1.1×	314 1.1×	233 1.6×	131 1.0×	130 1.5×	10	696
DR Head United States	9	525 1.0×	309 1.0×	341 2.3×	127 1.0×	210 2.5×	10	765

Countries citing papers authored by F Beeldens

Since Specialization

Citations

This map shows the geographic impact of F Beeldens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Beeldens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Beeldens more than expected).

Fields of papers citing papers by F Beeldens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Beeldens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Beeldens. The network helps show where F Beeldens may publish in the future.

Co-authorship network of co-authors of F Beeldens

This figure shows the co-authorship network connecting the top 25 collaborators of F Beeldens. A scholar is included among the top collaborators of F Beeldens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Beeldens. F Beeldens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Colombo, Massimo, Simone I. Strasser, Petr Urbánek, et al.. (2013). 806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION. Journal of Hepatology. 58. S329–S330. 5 indexed citations

Lübbert, Michael, Stefan Suciu, Liliana Baila, et al.. (2011). Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology. 29(15). 1987–1996. 403 indexed citations

Wijermans, Pierre W., Stefan Suciu, Liliana Baila, et al.. (2008). Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood. 112(11). 226–226. 53 indexed citations

Amadori, Sergio, Stefan Suciu, Dominik Selleslag, et al.. (2008). Phase II–III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial. Blood. 112(11). 762–762. 2 indexed citations

Jehn, U., Stefan Suciu, Xavier Thomas, et al.. (2006). Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia. 20(10). 1723–1730. 17 indexed citations

Amadori, Sergio, Stefan Suciu, Roberto Stasi, et al.. (2005). Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia. 19(10). 1768–1773. 63 indexed citations

Suciu, Stefan, JP Marie, Augustin Ferrant, et al.. (2005). P-18 A new prognostic score foroutcome of patients with high-risk myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (SAML) after intensive antileukemic treatment. Leukemia Research. 29. S31–S31. 1 indexed citations

Amadori, Sergio, Stefan Suciu, R. Willemze, et al.. (2004). Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.. PubMed. 89(8). 950–6. 63 indexed citations

Amadori, Sergio, Stefan Suciu, Roel Willemze, et al.. (2004). Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study.. Blood. 104(11). 877–877. 3 indexed citations

10.

Suciu, Stefan, G. Verhoef, Boris Labar, et al.. (2003). The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 17(5). 859–868. 31 indexed citations

11.

Witte, T de, Stefan Suciu, Michel Delforge, et al.. (2001). Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups. Blood. 98(11). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact